RIPK1 and autoimmune disease: The development of RIPK1 inhibitors, such as GSK′772 for peripheral autoimmune diseases and DNL747 for central nervous system disorders, highlights their potential therapeutic application in mitigating the detrimental effects of RIPK1 activation [170].